Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Background: Nontuberculous Mycobacterium infections, particularly Mycobacterium abscessus, are increasingly common among patients with cystic fibrosis and chronic bronchiectatic lung diseases. Treatment is challenging due to intrinsic antibiotic resistance. Bacteriophage therapy represents a potentially novel approach. Relatively few active lytic phages are available and there is great variation in phage susceptibilities among M. abscessus isolates, requiring personalized phage identification. Methods: Mycobacterium isolates from 200 culture-positive patients with symptomatic disease were screened for phage susceptibilities. One or more lytic phages were identified for 55 isolates. Phages were administered intravenously, by aerosolization, or both to 20 patients on a compassionate use basis and patients were monitored for adverse reactions, clinical and microbiologic responses, the emergence of phage resistance, and phage neutralization in serum, sputum, or bronchoalveolar lavage fluid. Results: No adverse reactions attributed to therapy were seen in any patient regardless of the pathogen, phages administered, or the route of delivery. Favorable clinical or microbiological responses were observed in 11 patients. Neutralizing antibodies were identified in serum after initiation of phage delivery intravenously in 8 patients, potentially contributing to lack of treatment response in 4 cases, but were not consistently associated with unfavorable responses in others. Eleven patients were treated with only a single phage, and no phage resistance was observed in any of these. Conclusions: Phage treatment of Mycobacterium infections is challenging due to the limited repertoire of therapeutically useful phages, but favorable clinical outcomes in patients lacking any other treatment options support continued development of adjunctive phage therapy for some mycobacterial infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“successfully used to treat chronic, drug-resistant infections of M. abscessus (177–179)”
From Mycobacterium smegmatis: The Vanguard of Mycobacterial Research (2023) · cites this paper as [178]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Phages have also been explored as diagnostic tools, and successfully used to treat chronic, drug-resistant infections of M. abscessus (177–179).”
From Mycobacterium smegmatis: The Vanguard of Mycobacterial Research (2023) · cites this paper as [178]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dedrick, R. M., Guerrero-Bustamante, C. A., Garlena, R. A., Russell, D. A., Ford, K., Harris, K., Gilmour, K. C., Soothill, J., Jacobs-Sera, D., Schooley, R. T., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0437-z · Cited by 1,410
Self-citationSchooley, R. T., Biswas, B., Gill, J. J., Hernandez-Morales, A., Lancaster, J., Lessor, L., Barr, J. J., Reed, S. L., Rohwer, F., Benler, S., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00954-17 · Cited by 1,254
Self-citationJault, P., Leclerc, T., Jennes, S., Pirnay, J. P., Que, Y.-A., Resch, G., Rousseau, A. F., Ravat, F., Carsin, H., Le Floch, R., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30482-1 · Cited by 874
Daley, C. L., Iaccarino, J. M., Lange, C., Cambau, E., Wallace, R. J., Andrejak, C., Böttger, E. C., Brozek, J., Griffith, D. E., Guglielmetti, L., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1125 · Cited by 786
Bustamante, J., Boisson-Dupuis, S., Abel, L., & Casanova, J.-L. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.09.008 · Cited by 684
Phage Therapy for Antibiotic-Resistant Bacterial Infections
Hatfull, G. F., Dedrick, R. M., & Schooley, R. T. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-080219-122208 · Cited by 571
Self-citationSarker, S. A., Sultana, S., Reuteler, G., Moine, D., Descombes, P., Charton, F., Bourdin, G., McCallin, S., Ngom-Bru, C., Neville, T., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2015.12.023 · Cited by 533
Phage treatment of an aortic graft infected with Pseudomonas aeruginosa
Chan, B. K., Turner, P. E., Kim, S., Mojibian, H. R., Elefteriades, J. A., & Narayan, D. (2018) · Evolution, Medicine, and Public Health · doi:10.1093/emph/eoy005 · Cited by 501
Aslam, S., Lampley, E., Wooten, D., Karris, M., Benson, C., Strathdee, S., & Schooley, R. T. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa389 · Cited by 342
Self-citationNick, J. A., Dedrick, R. M., Gray, A. L., Vladar, E. K., Smith, B. E., Freeman, K. G., Malcolm, K. C., Epperson, L. E., Hasan, N. A., Hendrix, J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.04.024 · Cited by 251 · cited 1×
“chelonae skin infection (patient 16); details of patients 15 and 16 were recently reported [22, 23].”
BackgroundSelf-citation
Research works printed but not linked: 1
- Guerrero-Bustamante, 2021, Toward a phage cocktail for tuberculosis: susceptibility and tuberculocidal action of mycobacteriophages against diverse Mycobacterium tuberculosis strains, mBio, 12, e00973-21, 10.1128/mbio.00973-21 · DOI · Paper page
Cited by
Items 101–200 of 416
The Role of Genomics in Advancing and Standardising Bacteriophage Therapy
Абдраймова, Н. К., Shitikov, E. A., & Kornienko, M. A. (2026) · Antibiotics · doi:10.3390/antibiotics15010055 · Cited by 16
Rubio, A., Sprang, M., Garzón, A., Moreno-Rodríguez, A., Pachón-Ibáñez, M. E., Pachón, J., Andrade-Navarro, M. A., & Pérez‐Pulido, A. J. (2023) · Science Advances · doi:10.1126/sciadv.add8911 · Cited by 16
Phage Therapy for Urinary Tract Infections: Progress and Challenges Ahead
Morgan, C. J., Atkins, H., Wolfe, A. J., Brubaker, L. T., Aslam, S., Putonti, C., Doud, M. B., & Burnett, L. A. (2025) · International Urogynecology Journal · doi:10.1007/s00192-025-06136-8 · Cited by 16
A solution to the postantibiotic era: phages as precision medicine
Getz, L. J., Patel, P. H., & Maxwell, K. L. (2025) · Current Opinion in Microbiology · doi:10.1016/j.mib.2025.102613 · Cited by 16
Hassen, B., & Hammami, S. (2025) · Journal of Applied Microbiology · doi:10.1093/jambio/lxaf136 · Cited by 16
Therapeutic and Unconventional Strategies to Contrast Antimicrobial Resistance: A Literature Review
Vitiello, A., Sabbatucci, M., Boccellino, M., Ponzo, A., Langella, R., & Zovi, A. (2023) · Discovery Medicine · doi:10.24976/discov.med.202335178.70 · Cited by 16
Does Phage Therapy Need a Pan-Phage?
Bozidis, P., Markou, E., Gouni, A., & Gartzonika, K. (2024) · Pathogens · doi:10.3390/pathogens13060522 · Cited by 16
Phage Therapy in Lung Transplantation: Current Status and Future Possibilities
Aslam, S. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad528 · Cited by 15
Kenney, P., & Gomez-Duarte, O. G. (2024) · PLoS ONE · doi:10.1371/journal.pone.0298833 · Cited by 15
Antibacterial efficacy of mycobacteriophages against virulent Mycobacterium tuberculosis
Jeyasankar, S., Kalapala, Y. C., Sharma, P. R., & Agarwal, R. (2024) · BMC Microbiology · doi:10.1186/s12866-024-03474-3 · Cited by 15
Mycobacteriophages and Their Applications
Bonacorsi, A., Ferretti, C., Luca, M. D., & Rindi, L. (2024) · Antibiotics · doi:10.3390/antibiotics13100926 · Cited by 15
The ageing of people living with cystic fibrosis: what to expect now?
Montiel, A. F., Fernández, A. Á., Amigo, M. C., Traversi, L., Clofent, D., Loor, K., & Polverino, E. (2024) · European Respiratory Review · doi:10.1183/16000617.0071-2024 · Cited by 15
Discovery and characterisation of new phage targeting uropathogenic Escherichia coli
Kangachar, S. A., Logel, D. Y., Trofimova, E., Zhu, H. X., Zaugg, J., Schembri, M. A., Weynberg, K. D., & Jaschke, P. R. (2024) · Virology · doi:10.1016/j.virol.2024.110148 · Cited by 14
Ali, Z., Abdelkader, K., Abdel‐Fattah, M. M., Azmy, A. F., EL-Gendy, A. O., & Dishisha, T. (2025) · BMC Microbiology · doi:10.1186/s12866-025-03785-z · Cited by 14
Raman, S. K., Roy, T., Verma, K., Yadav, C., Verma, S., Deivreddy, V. S. R., Sofi, H. S., Bharti, R., Sharma, R., Bansode, H., et al. (2025) · Tuberculosis · doi:10.1016/j.tube.2025.102631 · Cited by 14
Hodgkinson‐Bean, J., Ayala, R., Jayawardena, N., Rutter, G. L., Watson, B. N. J., Mayo-Muñoz, D., Keal, J. A., Fineran, P. C., Wolf, M., & Bostina, M. (2025) · Nature Communications · doi:10.1038/s41467-025-58514-x · Cited by 14
Bacteriophage-based strategies for biocontrol and treatment of infectious diseases
Nhung, T. T. T., Verma, S., Ponne, S., Meghwanshi, G. K., Schön, T., & Kumar, R. (2025) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2025.06.046 · Cited by 14
Engineered bacteriophages for therapeutic and diagnostic applications
Traore, K., Seyer, D., Mihajlovski, A., & Sagona, A. P. (2025) · Disease Models & Mechanisms · doi:10.1242/dmm.052393 · Cited by 14
Gorodnichev, R. B., Shitikov, E. A., Gurkova, M. M., Kochetova, T., Petrova, M., Kuzovlev, A. N., Bespiatykh, D., Malakhova, M. V., Zaychikova, M. V., Krivulia, A. O., et al. (2026) · Critical Care · doi:10.1186/s13054-026-05839-8 · Cited by 14
The role of the animal host in the management of bacteriophage resistance during phage therapy
Gaborieau, B., & Debarbieux, L. (2022) · Current Opinion in Virology · doi:10.1016/j.coviro.2022.101290 · Cited by 14
Unusual prophages in Mycobacterium abscessus genomes and strain variations in phage susceptibilities
Amarh, E. D., Dedrick, R. M., Garlena, R. A., Russell, D. A., Gauthier, C. H., Aull, H. G., Abad, L., Jacobs‐Sera, D., Akusobi, C., Rubin, E. J., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281769 · Cited by 14
Self-citationExploring the advancements of Australian OPAT
Lai, T., Thiele, H., Rogers, B. A., Hillock, N. T., Adhikari, S., McNamara, A., & Rawlins, M. D. M. (2023) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361231199582 · Cited by 14
Phage therapy: A renewed approach against oral diseases caused by Enterococcus faecalis infections
Yang, D., Xiang, Y., Song, F., Li, H., & Ji, X. (2024) · Microbial Pathogenesis · doi:10.1016/j.micpath.2024.106574 · Cited by 14
Resistance to bacteriophage incurs a cost to virulence in drug-resistant Acinetobacter baumannii
Manley, R., Fitch, C. P., Francis, V., Temperton, I., Turner, D., Fletcher, J., Phil, M., Michell, S., & Temperton, B. (2024) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001829 · Cited by 14
Trehalose polyphleates participate in Mycobacterium abscessus fitness and pathogenesis
Malmsheimer, S., Daher, W., Tasrini, Y., Hamela, C., Aguilera-Correa, J. J., Chalut, C., Hatfull, G. F., & Kremer, L. (2024) · mBio · doi:10.1128/mbio.02970-24 · Cited by 13
Self-citationLeveraging mathematical modeling framework to guide regimen strategy for phage therapy
Yu, Z., Luong, T., Bañuelos, S., Sue, A. D., Ryu, H., Segal, R. A., Roach, D. R., & Huang, Q. (2024) · PLOS complex systems. · doi:10.1371/journal.pcsy.0000015 · Cited by 13
Liu, Y., Thong, S., Moreira, W., Yeo, J. H., Zhong, Y., Chong, Z.-S., Wong, T. H. N., Chung, S. J., & Kwa, A. L. (2025) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2025.107570 · Cited by 13
Anti-interferon-γ autoantibodies syndrome and opportunistic infections: systematic literature review
Chen, N., Hong, L., Liang, H., Yu, Q., Liang, S., & He, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1615091 · Cited by 13
Alsaadi, A., Imam, M., Alghamdi, A. A. M., & Alghoribi, M. F. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.10.022 · Cited by 13
Applications of designer phage encoding recombinant gene payloads
Schmitt, D. S., Siegel, S. D., & Selle, K. (2023) · Trends in biotechnology · doi:10.1016/j.tibtech.2023.09.008 · Cited by 13
Antimicrobials: An update on new strategies to diversify treatment for bacterial infections
Hibbert, T. M., Krpetić, Ž., Latimer, J., Leighton, H. J., McHugh, R. E., Pottenger, S., Wragg, C., & James, C. E. (2024) · Advances in microbial physiology/Advances in Microbial Physiology · doi:10.1016/bs.ampbs.2023.12.002 · Cited by 13
Mycobacteriophages: therapeutic approach for mycobacterial infections
Raman, S. K., Reddy, D. V. S., Jain, V. P., Bajpai, U., Misra, A., & Singh, A. K. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104049 · Cited by 13
Evaluation of host immune responses to Mycobacteriophage Fionnbharth by route of delivery
Smytheman, T., Pecor, T., Miller, D. E., Ferede, D., Kaur, S., Harband, M. H., Abdelaal, H. F. M., Guerrero-Bustamante, C. A., Freeman, K. G., Harrington, W. E., et al. (2025) · Virology Journal · doi:10.1186/s12985-024-02552-2 · Cited by 12
Self-citationAn update on experimental to large-scale production of bacteriophages against superbugs: a review
Rahimian, M., Mohammadi, E., Aghazadeh-Soltan-Ahmadi, M., Samari, A., & Zarghami, N. (2025) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2025.2531446 · Cited by 12
Kapoor, H., Maves, A. M., Bowder, M. A., & Danelishvili, L. (2025) · Scientific Reports · doi:10.1038/s41598-025-07320-y · Cited by 12
Genome synthesis, assembly, and rebooting of therapeutically useful high G+C% mycobacteriophages
Ko, C., Sikkema, A. P., Lauer, M. J., Amarh, E. D., Garlena, R. A., Russell, D. A., Chew, N., Li, T., Harrison, I. M., Ellefson, J. W., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2523871122 · Cited by 12
Self-citationExploring bacteriophage therapy for drug-resistant bacterial infections.
Schooley, R. T. (2023) · PubMed Central · Cited by 12
Self-citationAutomating Predictive Phage Therapy Pharmacology
Abedon, S. T. (2023) · Antibiotics · doi:10.3390/antibiotics12091423 · Cited by 12
The untapped potential of phage model systems as therapeutic agents
Dherbey, J. R., & Bertels, F. (2024) · Virus Evolution · doi:10.1093/ve/veae007 · Cited by 12
Drug-resistant tuberculosis: a priority pathogen for enhanced public health research and practice
Yapa, H. M., MacLean, E. L.-H., Menzies, N. A., Dodd, P. J., Dean, A. S., Mirzayev, F., Schumacher, S. G., Nguyen, L. N., Zignol, M., & Fox, G. J. (2025) · Clinical Microbiology Reviews · doi:10.1128/cmr.00064-25 · Cited by 11
Altamirano, F. L. G., Subedi, D., Beiers, M., Bucher, M. J., Dahlman, S., Patel, D. M., Parker, M., Korneev, D., Robinson, M. J., Pragastis, K., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04301-0 · Cited by 11
Overcoming Bacteriophage Resistance in Phage Therapy
Laanto, E. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3549-0_23 · Cited by 11
Lee, S., Lynch, S. A., Lin, R. C. Y., Myung, H., & Iredell, J. R. (2023) · Infection and Chemotherapy · doi:10.3947/ic.2023.0067 · Cited by 11
Self-citationSui, B., Li, X., Li, N., Tao, Y., Wang, L., Xu, Y., Hou, Y., Hu, B., & Tan, D. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.01601-24 · Cited by 11
Using a human colonoid-derived monolayer to study bacteriophage translocation
Le, H. T., Fajardo-Lubian, A., Bowring, B. G., van der Poorten, D., Iredell, J. R., George, J., Venturini, C., Ahlenstiel, G., & Read, S. A. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2331520 · Cited by 11
Self-citationThe Appearance of Antiphage Antibodies in Sera of Patients Treated with Phages
Łusiak-Szelachowska, M., Weber‐Dąbrowska, B., Żaczek, M., Międzybrodzki, R., & Górski, A. (2025) · Antibiotics · doi:10.3390/antibiotics14010087 · Cited by 10
Skin microbiome engineering: Challenges and opportunities in skin diseases treatment
Lyu, Y., Shen, J., Che, Y., & Dai, L. (2025) · iMetaOmics. · doi:10.1002/imo2.70012 · Cited by 10
Pharmacokinetics and pharmacodynamics of bacteriophage therapy: A scoping review
Nguyen, A. T., Mehta, N., Mackey, K., Cummiskey, T., Rodriguez, E. K., & Young, J. (2026) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2025.107705 · Cited by 10
Managing Patient and Clinician Expectations of Phage Therapy in the United Kingdom
Jones, J. D., Stacey, H. J., Brailey, A., Suleman, M., & Langley, R. J. (2023) · Antibiotics · doi:10.3390/antibiotics12030502 · Cited by 10
Characterization of the Attachment of Three New Coliphages onto the Ferrichrome Transporter FhuA
Lewis, J. M., Janda, K. E., Kotter, D. B., Grose, J. H., & McCleary, W. R. (2023) · Journal of Virology · doi:10.1128/jvi.00667-23 · Cited by 10
Rao, G. G., Vallé, Q., Mahadevan, R., Sharma, R., Barr, J. J., & Tyne, D. V. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3426 · Cited by 10
Phage therapy in the management of respiratory and pulmonary infections: a systematic review
Sarkodie-Addo, P., Osman, A.-H., Aglomasa, B. C., & Donkor, E. S. (2025) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361241307841 · Cited by 9
Phage Therapy for Bone and Joint Infections: Towards Clinical Translation
Ortiz-Cartagena, C., Blasco, L., Bleriot, I., Esteban, J., del Toro, M. D., del Pozo, J. L., & Tomás, M. (2025) · Antibiotics · doi:10.3390/antibiotics14121187 · Cited by 9
A Way Forward for Phage Therapy in the United States
Swenson, K., Gonzalez, J., & Steen, T. Y. (2024) · Georgetown Medical Review · doi:10.52504/001c.117696 · Cited by 9
Degiacomi, G., Chiarelli, L. R., Riabova, O., Lorè, N. I., Muñoz-Muñoz, L., Recchia, D., Stelitano, G., Postiglione, U., Saliu, F., Griego, A., et al. (2024) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2024.107278 · Cited by 9
Discovery and characterization of a novel LysinB from F2 sub-cluster mycobacteriophage RitSun
Arora, R., Nadar, K., & Bajpai, U. (2024) · Scientific Reports · doi:10.1038/s41598-024-68636-9 · Cited by 9
Bacteriophage discovery to advance biotechnology and biotherapeutics
Mu, A., & Lawley, T. D. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00870-w · Cited by 9
Phages for treatment of Escherichia coli infections
Nikulin, N. A., Karmanova, A. N., Zimin, A. A., & Aminov, R. I. (2023) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.03.011 · Cited by 9
Cocorullo, M., Chiarelli, L. R., & Stelitano, G. (2023) · Vaccines · doi:10.3390/vaccines11071221 · Cited by 9
López‐Medrano, F., Carver, P. L., Rutjanawech, S., Aranha-Camargo, L. F., Fernandes, R. D. A., Belga, S., Daniels, S.-A., Mueller, N. J., Burkhard, S., Theodoropoulos, N. M., et al. (2024) · Transplantation · doi:10.1097/tp.0000000000005156 · Cited by 9
Pulmonary Delivery of Antibiotics to the Lungs: Current State and Future Prospects
Dallal Bashi, Y. H., Mairs, R., Murtadha, R., & Kett, V. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17010111 · Cited by 8
Nie, X., Tong, Y., Li, M., Ning, Z., & Fan, H. (2025) · Microbiological Research · doi:10.1016/j.micres.2025.128231 · Cited by 8
Preclinical Evidence for Phage Therapy to Treat Mycobacterial Infections: A Narrative Review
Janssen, S., Larsen, S. E., Morrow, C., Ramsubag, B., Torres, M. P., Guerrero-Bustamante, C. A., Coler, R. N., van Ingen, J., Hatfull, G. F., & Diacon, A. H. (2025) · PHAGE · doi:10.1089/phage.2024.0059 · Cited by 8
Self-citationTowards airway microbiome engineering for improving respiratory health
Hern, K. E., & Prindle, A. B. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115662 · Cited by 8
Phage therapy: Innovative approaches for refractory pulmonary infections
Qian, Y., Zhu, Z., Zhu, J., Chen, L., & Du, H. (2025) · Virus Research · doi:10.1016/j.virusres.2025.199649 · Cited by 8
Jones, J. D., Ferguson, P. R., & Suleman, M. (2022) · Journal of Patient Safety and Risk Management · doi:10.1177/25160435221120300 · Cited by 8
Harman-McKenna, V. K., & Buck, J. D. (2023) · Viruses · doi:10.3390/v16010020 · Cited by 8
Characterization of mycobacteriophage Adephagia cytotoxic proteins
Freeman, K. G., Lauer, M. J., Jiang, D., Roscher, J., Sandler, S., Mercado, N., Fryberger, R., Kovalski, J. M., Lutz, A. R., Hughes, L. E., et al. (2024) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkae166 · Cited by 8
Self-citationEmerging and alternative strategies for the treatment of nontuberculous mycobacterial infections
Sreekumar, A., Kumar, A., Biswas, R., & Biswas, L. (2024) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2024.2395003 · Cited by 8
Tsoumbris, P. R., Vincent, R. M., & Jaschke, P. R. (2024) · Archives of Virology · doi:10.1007/s00705-024-06170-9 · Cited by 8
Phages for the treatment of Mycobacterium species
Opperman, C. J., Wojno, J., Goosen, W. J., & Warren, R. M. (2023) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.03.016 · Cited by 8
Phage Therapy for Hospital-Acquired Respiratory Bacterial Infections: A Review
Muñoz-Egea, M.-C., Rodríguez, A., Esteban, J., & García‐Quintanilla, M. (2025) · Open Respiratory Archives · doi:10.1016/j.opresp.2025.100507 · Cited by 7
Yang, X., Wu, N., Jiang, X., Cheng, M., Hu, L., Li, N., Fang, Y., Yu, X., Ji, J., Ding, X., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69154-0 · Cited by 7
Bhale, B. S., Shirodkar, S., Sawarkar, S. P., & Omri, A. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2632669 · Cited by 7
Phage therapy in people with cystic fibrosis: A systematic review
Terlizzi, V., Rinninella, G., Viglietto, L., D’Agosto, A., Luca, M. D., Lopes‐Pacheco, M., & Chiappini, E. (2026) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2026.108581 · Cited by 7
Understanding the influence of the microbiome on childhood infections
Heston, S. M., Hurst, J. H., & Kelly, M. S. (2024) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2024.2340664 · Cited by 7
New antibiofilm strategies for the management of nontuberculous mycobacteria diseases
Cano-Fernández, M., & Esteban, J. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2412250 · Cited by 7
Tellez-Carrasquilla, S., Salazar‐Ospina, L., & Jiménez, J. N. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1502593 · Cited by 7
Vic9 mycobacteriophage: the first subcluster B2 phage isolated in Russia
Zaychikova, M. V., Malakhova, M. V., Bespiatykh, D., Kornienko, M. A., Klimina, K. M., Strokach, A. A., Gorodnichev, R. B., German, A., Fursov, M. V., Bagrov, D. V., et al. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1513081 · Cited by 7
The role of colony morphotype in shaping gene essentiality in Mycobacteroides abscessus
Ross, B. N., Evans, E., Diggle, F. L., Briaud, P., & Whiteley, M. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2500719122 · Cited by 7
Martiniano, S. L., Caceres, S. M., Poch, K. R., Rysavy, N., Lovell, V. K., Armantrout, E., Jones, M. C., Anthony, M., Keck, A., Nichols, D. P., et al. (2023) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2023.08.007 · Cited by 7
Self-citationBacteriophages for bronchiectasis: treatment of the future?
Dominic, C., Pye, H. V., Mishra, E. K., & Adriaenssens, E. M. (2024) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001050 · Cited by 7
Gangakhedkar, R., & Jain, V. P. (2024) · Molecular Microbiology · doi:10.1111/mmi.15295 · Cited by 7
Estudios farmacocinéticos y farmacodinámicos de la fagoterapia
Blasco, L., Bleriot, I., Fernández-Grela, P., Paño‐Pardo, J. R., Oteo, J., & Tomás, M. (2025) · Farmacia Hospitalaria · doi:10.1016/j.farma.2025.04.003 · Cited by 7
Brüssow, H. (2023) · Microbiome Research Reports · doi:10.20517/mrr.2022.20 · Cited by 7
Personalized bacteriophage therapy for difficult-to-treat infections
Iredell, J. R., Sinclair, H., & Khatami, A. (2024) · Nature Microbiology · doi:10.1038/s41564-024-01712-y · Cited by 7
Self-citationA review on re-emerging bacteriophage therapy in the era of XDR
Bhadoriya, P., Sharma, R., Mehrotra, R., KAUR, S., SRIVASTAVA, I., Jain, M., & Kaushik, P. (2023) · Biocell · doi:10.32604/biocell.2023.029564 · Cited by 6
Biophysical Breakthroughs Projected for the Phage Therapy of Bacterial Disease
Chambers, J. P., Aldis, M., Thomas, J. A., Gonzales, C. B., White, R. A., III, & Serwer, P. (2024) · Biophysica · doi:10.3390/biophysica4020014 · Cited by 6
Translational research priorities for bacteriophage therapeutics
Schooley, R. T. (2024) · Essays in Biochemistry · doi:10.1042/ebc20240020 · Cited by 6
Self-citationGolla, A. C., Chaumontet, J., Voorde, R. V., & Danelishvili, L. (2024) · Antibiotics · doi:10.3390/antibiotics13111009 · Cited by 6
Mycobacterium abscessus group pulmonary disease
Griffith, D. E. (2025) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000001101 · Cited by 6
Insights on the Pathogenesis of Mycobacterium abscessus Infection in Patients with Cystic Fibrosis
Basher, M., Gur, M., & Meir, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103492 · Cited by 6
An update on targeting airway inflammation in cystic fibrosis
Mullen, E., Murphy, M. P., Bateman, G., Casey, M., Gunaratnam, C., & McElvaney, N. G. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2517898 · Cited by 6
Consensus on the management of refractory nontuberculous mycobacterial pulmonary disease
Moreira‐Sousa, D., Martins, B., Aguiar, A., Pinheiro, M., Akkerman, O. W., Aksamit, T. R., Aliberti, S., Andréjak, C., Daley, C. L., van Ingen, J., et al. (2025) · European Respiratory Journal · doi:10.1183/13993003.00400-2025 · Cited by 6
Current Advances in Developing New Antimicrobial Agents Against Non-Tuberculous Mycobacterium
Cross, J., Gargate, N., & Rahman, K. M. (2025) · Antibiotics · doi:10.3390/antibiotics14121189 · Cited by 6
Analysis of Pro- and Anti-Inflammatory Gene Response Patterns in Patients Receiving Phage Therapy
Kasprzak, H., Przybylski, M., Fortuna, W., Letkiewicz, S., Rogóż, P., Bubak, B., Górski, A., & Międzybrodzki, R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010172 · Cited by 6
Moreira‐Sousa, D., Martins, B., Aguiar, A., Pinheiro, M., Akkerman, O. W., Aksamit, T. R., Aliberti, S., Andréjak, C., Daley, C. L., van Ingen, J., et al. (2026) · Pulmonology · doi:10.1080/25310429.2026.2632467 · Cited by 6
Phage therapy: from basic biology to clinical application
Sinclair, H., Lin, R. C. Y., Zakour, N. L. B., Bollyky, P. L., & Iredell, J. R. (2026) · Nature Reviews Microbiology · doi:10.1038/s41579-026-01352-5 · Cited by 6
Self-citationThe potential of bacteriophages in treating multidrug-resistant ESKAPE pathogen infections
Faccin, I. D., de Souza, G. H. D. A., Vicente, J. C. P., Damaceno, N. D. S., Perez, E. V. D. O., Martins, W. M. B. S., Gales, A. C., & Simionatto, S. (2025) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2025.2545784 · Cited by 6
Pharmacokinetics and pharmacodynamics studies of phage therapy
Blasco, L., Bleriot, I., Fernández-Grela, P., Paño‐Pardo, J. R., Oteo, J., & Tomás, M. (2025) · Farmacia Hospitalaria · doi:10.1016/j.farma.2025.07.007 · Cited by 6
Metadata
- Authors
- Dedrick, R. M., Smith, B. E., Cristinziano, M., Freeman, K. G., Jacobs-Sera, D., Belessis, Y., Whitney Brown, A., Cohen, K. A., Davidson, R. M., van Duin, D., Gainey, A., Garcia, C. B., Robert George, C. R., Haidar, G., Ip, W., Iredell, J., Khatami, A., Little, J. S., Malmivaara, K., McMullan, B. J., Michalik, D. E., Moscatelli, A., Nick, J. A., Tupayachi Ortiz, M. G., Polenakovik, H. M., Robinson, P. D., Skurnik, M., Solomon, D. A., Soothill, J., Spencer, H., Wark, P., Worth, A., Schooley, R. T., Benson, C. A., & Hatfull, G. F.
- Affiliations
- University of Pittsburgh (US)
- Department of Biological Sciences, University of Pittsburgh , Pittsburgh, Pennsylvania , USA
- UNSW Sydney (AU)
- Inova Fairfax Hospital , Falls Church, Virginia , USA
- Johns Hopkins University (US)
- National Jewish Health (US)
- Division of Infectious Diseases, University of North Carolina , Chapel Hill, North Carolina , USA
- Prisma Health (US)
- Department of Respiratory Disease, Hospital Universitari Vall d’Hebron , Barcelona , Spain
- New South Wales Health Pathology Microbiology, John Hunter Hospital , New Lambton, New South Wales , Australia
- Great Ormond Street Hospital (GB)
- Sydney Children's Hospital (AU)
- Children's Hospital at Westmead (AU)
- Brigham and Women's Hospital (US)
- Miller Children's & Women's Hospital (US)
- Istituto Giannina Gaslini (IT)
- Department of Medicine, Division of Pulmonary and Critical Care Medicine, Miller School of Medicine, University of Miami , Miami, Florida , USA
- Wright State University (US)
- University of Helsinki (FI)
- Hunter Medical Research Institute (AU)
- University of California San Diego (US)
- Corresponding author
- Hatfull, Graham F
- ORCID
- Dedrick, Rebekah M
- Smith, Bailey E
- Freeman, Krista G
- Belessis, Yvonne
- Cohen, Keira A
- Davidson, Rebecca M
- Gainey, Andrew
- Haidar, Ghady
- Ip, Winnie
- Iredell, Jonathan
- Khatami, Ameneh
- Little, Jessica S
- McMullan, Brendan J
- Michalik, David E
- Moscatelli, Andrea
- Nick, Jerry A
- Polenakovik, Hari M
- Robinson, Paul D
- Skurnik, Mikael
- Solomon, Daniel A
- Spencer, Helen
- Wark, Peter
- Worth, Austen
- Schooley, Robert T
- Benson, Constance A
- Hatfull, Graham F
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-06-09
- Volume
- 76
- Issue
- 1
- Pages
- 103-112
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC9825826
- OpenAlex
- W4281760779
- Cited by
- 344
- References
- 23
- Citations by year
- 2026: 74 · 2025: 89 · 2024: 91 · 2023: 72 · 2022: 18
- FWCI
- 35.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Clinical Infectious Diseases (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- Työväentutkimus Vuosikirja (submittedVersion)
- Funders
- Howard Hughes Medical Institute (GT12053)
- Cystic Fibrosis Foundation (HATFUL19GO, NICK20Y2-SVC, NICK20Y2-OUT)
- National Heart, Lung, and Blood Institute (K08 HL139994-01)
- Burroughs Wellcome Fund (HL146228, NICK20Y2-SVC and NICK20Y2-OUT)
- NIH (GM131729, AI154546, R01HL146228)
- Jane and Aatos Erkko Foundation
- Topics
- Life Sciences › Immunology and Microbiology › Virology › Bacteriophages and microbial interactions
- Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Keywords
- phage therapy, Mycobacterium abscessus, nontuberculous mycobacterial infection, cystic fibrosis, phage resistance, neutralizing antibodies, phage neutralization, compassionate use, adjunctive therapy
- MeSH terms
- Phage Therapy, Anti-Bacterial Agents, Bacteriophages, Cystic Fibrosis, Pharmaceutical Preparations, Humans, Mycobacterium, Mycobacterium Infections, Nontuberculous, Compassionate Use Trials
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.